- Home
- EYPT vs VSTM Comparison
EYPT vs VSTM Comparison
Compare EYPT & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- VSTM
- Stock Information
- Founded
- EYPT 1987
- VSTM 2010
- Country
- EYPT United States
- VSTM United States
- Employees
- EYPT N/A
- VSTM N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- VSTM Health Care
- Exchange
- EYPT Nasdaq
- VSTM Nasdaq
- Market Cap
- EYPT 484.4M
- VSTM 425.9M
- IPO Year
- EYPT 2005
- VSTM 2012
- Fundamental
- Price
- EYPT $10.37
- VSTM $4.16
- Analyst Decision
- EYPT Strong Buy
- VSTM Strong Buy
- Analyst Count
- EYPT 8
- VSTM 9
- Target Price
- EYPT $24.75
- VSTM $12.63
- AVG Volume (30 Days)
- EYPT 817.0K
- VSTM 2.5M
- Earning Date
- EYPT 08-06-2025
- VSTM 08-07-2025
- Dividend Yield
- EYPT N/A
- VSTM N/A
- EPS Growth
- EYPT N/A
- VSTM N/A
- EPS
- EYPT N/A
- VSTM N/A
- Revenue
- EYPT $56,042,000.00
- VSTM $10,000,000.00
- Revenue This Year
- EYPT N/A
- VSTM $129.06
- Revenue Next Year
- EYPT N/A
- VSTM $306.32
- P/E Ratio
- EYPT N/A
- VSTM N/A
- Revenue Growth
- EYPT 12.04
- VSTM N/A
- 52 Week Low
- EYPT $3.91
- VSTM $2.10
- 52 Week High
- EYPT $13.99
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- EYPT 72.76
- VSTM 24.83
- Support Level
- EYPT $7.94
- VSTM $4.43
- Resistance Level
- EYPT $10.77
- VSTM $6.62
- Average True Range (ATR)
- EYPT 0.74
- VSTM 0.32
- MACD
- EYPT 0.10
- VSTM -0.18
- Stochastic Oscillator
- EYPT 85.87
- VSTM 1.01
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.